(Q36984231)

17 August 2017

1 reference

title

The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia (English)

1 reference

17 August 2017

0 references

Edoardo Spina

1

1 reference

17 August 2017

Roberto Cavallaro

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Drug Safety

17 August 2017

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

651-662

1 reference

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Paliperidone extended release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

21 January 2018

Paliperidone: quo vadis?

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Survey on the pharmacodynamics of the new antipsychotic risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

An update of fast-off dopamine D2 atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Metabolic drug interactions with newer antipsychotics: a comparative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Risperidone and paliperidone inhibit p-glycoprotein activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.651

21 January 2018

Identifiers

DOI

10.1517/14740338.6.6.651

1 reference

17 August 2017

1 reference